This post was originally published on this site Rare diseases deeply affect not only the children who experience them, but also their healthy brothers and sisters, as their parents can attest. Two entries in November’s “Disorder: The Rare Disease Film Festival” will focus on what siblings go through, according to the San Francisco festival’s…
This post was originally published on this site A research team at the David Geffen School of Medicine at UCLA received a $1.8 million, five-year grant from the National Institutes of Health (NIH) to develop new therapeutic and preventive strategies for ovarian cancer based on the tumor suppressor p53. The team, led by Alice Soragni,…
This post was originally published on this site The European Commission (EC) has approved Empliciti (elotuzumab) in combination with Pomalyst (pomalidomide) and low-dose dexamethasone for the treatment of adults with relapsed and refractory multiple myeloma. The therapy, collectively known as the EPd combo, is intended for patients who received at least two prior therapies, including…
This post was originally published on this site A Phase 2 clinical trial of WP1220, a potential topical treatment of cutaneous T-cell lymphoma (CTCL) lesions, has reached full patient enrollment. Developed by Moleculin Biotech, WP1220 is an inhibitor of phospho (p)-STAT3, the activated form of a transcription factor key for cancer cell growth and survival.…
This post was originally published on this site Adding the cancer vaccine Pexa-Vec to Nexavar (sorafenib), a standard of care, is not likely to improve overall survival of patients with advanced liver cancer, an interim analysis by the independent data monitoring committee of the PHOCUS Phase 3 trial reported. Based on these findings, the committee is…
This post was originally published on this site The European Commission has approved the use of Roche‘s Tecentriq (atezolizumab) in combination with Abraxane (nab-paclitaxel) chemotherapy to treat certain adults with advanced triple-negative breast cancer (TNBC), an aggressive and difficult-to-treat malignancy. The combo is intended for people whose tumors cannot be removed by surgery (unresectable), are locally advanced or…
This post was originally published on this site This week, pet lovers across the United States celebrated National Dog Day to bring awareness to the thousands of dogs that need rescuing. My golden retriever is celebrated every day. A last act of love Jack isn’t an official service dog, but he is a helper to…
This post was originally published on this site A new 3D model using human cells grown on a chip can mimic what happens in the brain during Alzheimer’s and allow for the screening of possible therapies in a disease where so many fail, including medicines already approved for other conditions. This tissue model also helps…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has signed off on a clinical trial that will test CCW702, an immunotherapy developed by Calibr at Scripps Research, as a possible treatment of metastatic castration-resistant prostate cancer (mCRPC). CCW702 is a bispecific antibody, acting as a bridge between cancer and…
This post was originally published on this site Developing gene therapies for rare diseases is one thing. Creating gene-edited “designer babies” is quite another. German legal expert Timo Minssen outlined the potentially explosive ethical landmines surrounding such issues during a recent talk at the New York Genome Center. Minssen directs the Center for Advanced Studies…
